Vaxcyte, Inc.

NasdaqGS PCVX

Vaxcyte, Inc. Total Assets for the quarter ending September 30, 2024: USD 3.56 B

Vaxcyte, Inc. Total Assets is USD 3.56 B for the quarter ending September 30, 2024, a 137.94% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Vaxcyte, Inc. Total Assets for the quarter ending September 30, 2023 was USD 1.50 B, a 263.06% change year over year.
Vaxcyte, Inc. Total Assets for the quarter ending September 30, 2022 was USD 412.06 M, a 16.38% change year over year.
Vaxcyte, Inc. Total Assets for the quarter ending September 30, 2021 was USD 354.07 M.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

NasdaqGS: PCVX

Vaxcyte, Inc.

CEO	Mr. Grant E. Pickering M.B.A.
IPO Date	June 12, 2020
Location	United States
Headquarters	825 Industrial Road
Employees	254
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Key trends

Past 5 years